Dare Bioscience, Inc

AVANIR Pharmaceuticals is engaged in the research, discovery, development and licensing of innovative drug products used in the treatment of chronic diseases. Its product candidates address therapeutic markets that include the central nervous system, atherosclerosis, inflammatory diseases and infectious diseases. Its research and drug discovery programs are focused primarily on small molecules that can be taken orally as therapeutic treatments. The company's lead product candidate, Neurodex, is used for the treatment of Involuntary Emotional Expression Disorder, a condition also known as pseudobulbar affect or emotional lability. Also in clinical development is AVP 13358, a selective cytokine inhibitor. AVANIR was founded in 1988 and has corporate headquarters in San Diego. Its common shares trade on the NASDAQ under the ticker symbol AVNR.

Quidel Corporation, established in 1979, is one of the leading providers of diagnostic tests and solutions for detection and management of medical conditions and illnesses. It offers a variety of tests that aid in the diagnosis of several diseases, including influenza, fecal occult blood, bacterial vaginosis, infectious mononucleosis, pylori, chlamydia and pregnancy tests. The company markets its product under the brand name, QuickVue. It has a specialty products department that develops research products in the fields of oncology and bone health. The company also provides service and technical support to customers. Quidel Corporation has research and manufacturing operations in San Diego and Santa Clara, Calif.

Travere Therapeutics, Inc. is a San Diego-based biopharmaceutical company focused on developing life-changing therapies for individuals living with rare diseases, particularly in the fields of rare kidney and metabolic disorders. The company is dedicated to advancing science that has the potential to set new standards of care and improve patients' lives. With a strong commitment to patient advocacy, Travere engages with the community through initiatives like the "Play It Forward" campaign, aimed at raising awareness for conditions such as Focal Segmental Glomerulosclerosis (FSGS) and IgA Nephropathy (IgAN). Their mission is driven by the needs of patients, caregivers, and advocates, emphasizing resilience and support within the rare disease community. Generated from the website